28.91
1.06%
-0.31
After Hours:
28.91
Galapagos NV ADR stock is currently priced at $28.91, with a 24-hour trading volume of 138.47K.
It has seen a -1.06% decreased in the last 24 hours and a -13.47% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $29.30 pivot point. If it approaches the $28.78 support level, significant changes may occur.
Galapagos NV ADR Stock (GLPG) Financials Data
Galapagos NV ADR (GLPG) Revenue 2024
GLPG reported a revenue (TTM) of $261.10 million for the quarter ending December 31, 2023, a -1.12% decline year-over-year.
Galapagos NV ADR (GLPG) Net Income 2024
GLPG net income (TTM) was $228.29 million for the quarter ending December 31, 2023, a +201.30% increase year-over-year.
Galapagos NV ADR (GLPG) Cash Flow 2024
GLPG recorded a free cash flow (TTM) of -$460.37 million for the quarter ending December 31, 2023, a +18.78% increase year-over-year.
Galapagos NV ADR (GLPG) Earnings per Share 2024
GLPG earnings per share (TTM) was $3.4616 for the quarter ending December 31, 2023, a +200.86% growth year-over-year.
Galapagos NV ADR Stock (GLPG) Latest News
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
Zacks Investment Research
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Zacks Investment Research
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GlobeNewswire Inc.
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Zacks Investment Research
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
Zacks Investment Research
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
Zacks Investment Research
About Galapagos NV ADR
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Cap:
|
Volume (24h):